A Thorough QTc Study Confirms Early Pharmacokinetics/QTc Modeling: A Supratherapeutic Dose of Omarigliptin, a Once-Weekly DPP-4 Inhibitor, Does Not Prolong the QTc Interval-Reference-Cited by-同舟云学术

A Thorough QTc Study Confirms Early Pharmacokinetics/QTc Modeling: A Supratherapeutic Dose of Omarigliptin, a Once-Weekly DPP-4 Inhibitor, Does Not Prolong the QTc Interval

Published:2016-04-29 Issue:5 Volume:5 Page:383-392
ISSN:2160-763X
Container-title:Clinical Pharmacology in Drug Development
language:en
Short-container-title:Clinical Pharmacology in Drug Development

Author:

Tatosian Daniel A.¹,Cardillo Marricco Nadia²,Glasgow Xiaoli Shirley¹,DeGroot Bruce²,Dunnington Katherine²,George Laura¹,Gendrano Isaias Noel¹,Johnson-Levonas Amy O.¹,Swearingen Dennis²,Kauh Eunkyung¹

Affiliation:

1. Merck & Co., Inc; Kenilworth NJ USA

2. Celerion; Lincoln NE USA

Funder

Merck & Co., Inc.

Publisher

Wiley

Subject

Pharmacology (medical),Pharmaceutical Science

Reference8 articles.

1. Minireview: update on incretin biology: focus on glucagon-like peptide-1;Brubaker;Endocrinology,2010

2. The incretin system and its role in type 2 diabetes mellitus;Holst;Mol Cell Endocrinol,2009

3. Effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on beta-cell function in patients with type 2 diabetes: a model-based approach;Xu;Diabetes Obes Metab,2008

4. Accelerating drug development using biomarkers: a case study with sitagliptin, a novel DPP4 inhibitor for type 2 diabetes;Krishna;AAPS J,2008

5. A review of gliptins for 2014;Scheen;Expert Opin Pharmacother,2015

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prediction of pharmacokinetics and pharmacodynamics of trelagliptin and omarigliptin in healthy humans and in patients with renal impairment using physiologically based pharmacokinetic combined DPP-4 occupancy modeling;Biomedicine & Pharmacotherapy;2022-09

2. Repurposing of Omarigliptin as a Neuroprotective Agent Based on Docking with A2A Adenosine and AChE Receptors, Brain GLP-1 Response and Its Brain/Plasma Concentration Ratio after 28 Days Multiple Doses in Rats Using LC-MS/MS;Molecules;2021-02-08

3. Enhanced Extraction Technique of Omarigliptin from Human Plasma—Applied to Biological Samples from Healthy Human Volunteers;Molecules;2020-09-15

4. A Thorough QT Study to Evaluate the Effects of a Supratherapeutic Dose of Sertraline on Cardiac Repolarization in Healthy Subjects;Clinical Pharmacology in Drug Development;2020-04

5. Pharmacokinetic–pharmacodynamic (dipeptidyl peptidase‐4 inhibition) model to support dose rationale in diabetes patients, including those with renal impairment, for once‐weekly administered omarigliptin;British Journal of Clinical Pharmacology;2019-12